NCT05904080 2026-04-17
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
24 trialsNCT06064097 2026-04-17
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06980038 2026-04-16
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03010150 2026-04-15
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
M.D. Anderson Cancer Center
Recruiting
NCT06093061 2026-04-14
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
National Cancer Centre, Singapore
Phase 2 Recruiting
NCT06029270 2026-04-13
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07325539 2026-04-13
LIGHT
Sun Yat-sen University
Phase 2 Recruiting
NCT07201337 2026-04-06
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 3 Recruiting
NCT06532279 2026-04-03
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NCT05587543 2026-04-02
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
Fudan University
Phase EARLY_PHASE1 Recruiting
NCT06788002 2026-04-02
Light
Hunan Cancer Hospital
Phase 2 Recruiting
NCT05941741 2026-03-18
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Sun Yat-sen University
Phase 3 Recruiting
NCT07362979 2026-03-17
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT07459296 2026-03-16
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
First Affiliated Hospital of Guangxi Medical University
Phase 3 Recruiting
NCT07412314 2026-03-09
Proton Therapy for Recurrent Nasopharyngeal Carcinoma
Guangzhou Concord Cancer Center
Phase NA Recruiting
NCT06239727 2026-03-06
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Sun Yat-sen University
Phase 3 Recruiting
NCT06868433 2026-03-04
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Emory University
Phase 1 Recruiting
NCT07327216 2026-03-04
Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
Affiliated Hospital of Guangdong Medical University
Phase 3 Recruiting
NCT06059261 2026-02-18
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT06636734 2026-02-11
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Emory University
Phase 2 Recruiting
NCT06592599 2026-02-10
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Stanford University
Phase 2 Recruiting
NCT07101744 2026-01-23
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06475300 2026-01-21
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06976190 2026-01-20
Magic-C002
Shanghai Miracogen Inc.
Phase 3 Recruiting